ArticleJournal of family medicine and primary care2023
Adverse events following COVID-19 immunisation (AEFI) at a COVID-19 vaccination centre: An observational analytical study.
Article in Journal of family medicine and primary care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this study was to determine the adverse events following immunisation (AEFI) in various age groups after coronavirus disease 2019 (COVID-19) vaccination and assess the association of comorbidities with AEFI. Methods: An observational analytical study was conducted among the general population who had received both doses of the COVID-19 vaccine. A total of 389 participants from the 18-44 years age group, 380 participants from the 45-60 years age group and 373 participants from the 60 plus age group were enrolled in the study after verbal and written consent. Simple random sampling was used to select the study participant in each group. Home visits were made to fill out the semi-structured questionnaire for information regarding any adverse event following COVID-19 immunisation. Results: Overall, 31.9%, 19.74% and 15.17% of >60, 45-60 and 18-44 years, respectively, reported any AEFI after COVID-19 immunisation. The severity of AEFI was more among the 18-44 years age group (66.1%) followed by 45-60 years (30.67%) and less among the older one, that is, >60 years. Fever and pain with inflammation at the injection site were the most common AEFI reported after any dose. There was no association of comorbidity with the severity of AEFI. Conclusion: Since the AEFI reported are very less, most of them were of a minor type and were general immunogenic reactions of any vaccine. Hence the COVID-19 vaccines are very safe, and uptake should be high among all the recommended age groups to combat the severity of the COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.